156 related articles for article (PubMed ID: 24210059)
1. Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients.
Panomvana D; Traiyawong T; Towanabut S
J Pharm Pharm Sci; 2013; 16(4):502-10. PubMed ID: 24210059
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
3. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy.
Ramsay RE; McManus DQ; Guterman A; Briggle TV; Vazquez D; Perchalski R; Yost RA; Wong P
Ther Drug Monit; 1990 May; 12(3):235-41. PubMed ID: 2112276
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
5. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication.
Duncan JS; Patsalos PN; Shorvon SD
Epilepsia; 1991; 32(1):101-15. PubMed ID: 1985818
[TBL] [Abstract][Full Text] [Related]
6. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
[TBL] [Abstract][Full Text] [Related]
7. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data.
Battino D; Croci D; Rossini A; Messina S; Mamoli D; Perucca E
Epilepsia; 2003 Jul; 44(7):923-9. PubMed ID: 12823575
[TBL] [Abstract][Full Text] [Related]
8. The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.
Takeuchi T; Natsume J; Kidokoro H; Ishihara N; Yamamoto H; Azuma Y; Ito Y; Kurahashi N; Tsuji T; Suzuki M; Itomi K; Yamada K; Kurahashi H; Abe S; Okumura A; Maruyama K; Negoro T; Watanabe K; Kojima S
Brain Dev; 2016 Sep; 38(8):723-30. PubMed ID: 27033151
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.
May TW; Rambeck B; Jürgens U
Ther Drug Monit; 1996 Oct; 18(5):523-31. PubMed ID: 8885114
[TBL] [Abstract][Full Text] [Related]
10. Influence of coadministered antiepileptic drugs on serum phenobarbital concentrations in epileptic patients: quantitative analysis based on a suitable transforming factor.
Fukuoka N; Tsukamoto T; Uno J; Kimura M; Morita S
Biol Pharm Bull; 2004 Dec; 27(12):2000-5. PubMed ID: 15577220
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
Lu Q; Huang YT; Shu Y; Xu P; Xiang DX; Qu Q; Qu J
Medicine (Baltimore); 2018 Jul; 97(30):e11662. PubMed ID: 30045320
[TBL] [Abstract][Full Text] [Related]
12. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
[TBL] [Abstract][Full Text] [Related]
13. Rapid switchover to carbamazepine using pharmacokinetic parameters.
Kanner AM; Bourgeois BF; Hasegawa H; Hutson P
Epilepsia; 1998 Feb; 39(2):194-200. PubMed ID: 9578000
[TBL] [Abstract][Full Text] [Related]
14. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis.
Chuang YC; Chuang HY; Lin TK; Chang CC; Lu CH; Chang WN; Chen SD; Tan TY; Huang CR; Chan SH
Epilepsia; 2012 Jan; 53(1):120-8. PubMed ID: 22085257
[TBL] [Abstract][Full Text] [Related]
15. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population.
Wang XQ; Lang SY; Shi XB; Tian HJ; Wang RF; Yang F
Seizure; 2010 Nov; 19(9):562-6. PubMed ID: 20888266
[TBL] [Abstract][Full Text] [Related]
17. Drug interaction profile of topiramate.
Bourgeois BF
Epilepsia; 1996; 37 Suppl 2():S14-S17. PubMed ID: 8641241
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of therapeutic drug monitoring of antiepileptic drugs.
Irshaid YM; Hamdi AA; Al Homrany M
Int J Clin Pharmacol Ther; 2003 Mar; 41(3):126-31. PubMed ID: 12665161
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats.
Reeta KH; Mehla J; Pahuja M; Gupta YK
Pharmacol Biochem Behav; 2011 Sep; 99(3):399-407. PubMed ID: 21641922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
